Angiogenesis Inhibitors
Neovascularization, Pathologic
Neovascularization, Physiologic
Angiostatins
Thrombospondin 1
An extracellular matrix glycoprotein from platelets and a variety of normal and transformed cells of both mesenchymal and epithelial origin. Thrombospondin-1 is believed to play a role in cell migration and proliferation, during embryogenesis and wound repair. Also, it has been studied for its use as a potential regulator of tumor growth and metastasis.
Vascular Endothelial Growth Factor A
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Angiogenesis Inducing Agents
Collagen Type XVIII
Angiogenic Proteins
Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.
Endothelial Cells
Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.
Endothelium, Vascular
Allantois
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factors
Endothelial Growth Factors
These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.
Mice, Nude
Receptors, Vascular Endothelial Growth Factor
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
Lymphokines
Chorion
Human Umbilical Vein Endothelial Cells
Neoplasms
Cell Movement
Plasminogen
Fibroblast Growth Factor 2
A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).
Cell Division
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Corneal Neovascularization
New blood vessels originating from the corneal veins and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.
Neoplasm Transplantation
Isocoumarins
Chorioallantoic Membrane
Angiostatic Proteins
Xenograft Model Antitumor Assays
Antibiotics, Antineoplastic
Peptide Fragments
Kringles
Triple-looped protein domains linked by disulfide bonds. These common structural domains, so-named for their resemblance to Danish pastries known as kringlers, play a role in binding membranes, proteins, and phospholipids as well as in regulating proteolysis. Kringles are also present in coagulation-related and fibrinolytic proteins and other plasma proteinases.
Antigens, CD31
Indoles
Thrombospondins
A family of related, adhesive glycoproteins which are synthesized, secreted, and incorporated into the extracellular matrix of a variety of cells, including alpha granules of platelets following thrombin activation and endothelial cells. They interact with a number of BLOOD COAGULATION FACTORS and anticoagulant factors. Five distinct forms have been identified, thrombospondin 1, -2, -3, -4, and cartilage oligomeric matrix protein (COMP). They are involved in cell adhesion, platelet aggregation, cell proliferation, angiogenesis, tumor metastasis, VASCULAR SMOOTH MUSCLE growth, and tissue repair.
Collagen
Cells, Cultured
Blood Vessels
Umbilical Veins
Calreticulin
A multifunctional protein that is found primarily within membrane-bound organelles. In the ENDOPLASMIC RETICULUM it binds to specific N-linked oligosaccharides found on newly-synthesized proteins and functions as a MOLECULAR CHAPERONE that may play a role in PROTEIN FOLDING or retention and degradation of misfolded proteins. In addition calreticulin is a major storage form for CALCIUM and functions as a calcium-signaling molecule that can regulate intracellular calcium HOMEOSTASIS.
Vascular Endothelial Growth Factor Receptor-1
A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.
Neoplasms, Experimental
Tumor Cells, Cultured
Microvessels
Immunohistochemistry
Chick Embryo
Collagen Type IV
A non-fibrillar collagen found in the structure of BASEMENT MEMBRANE. Collagen type IV molecules assemble to form a sheet-like network which is involved in maintaining the structural integrity of basement membranes. The predominant form of the protein is comprised of two alpha1(IV) subunits and one alpha2(IV) subunit, however, at least six different alpha subunits can be incorporated into the heterotrimer.
Mice, SCID
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Intercellular Signaling Peptides and Proteins
Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.
Receptors, Growth Factor
Signal Transduction
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Reverse Transcriptase Polymerase Chain Reaction
Angiogenesis Modulating Agents
Disease Models, Animal
Neoplasm Metastasis
Apoptosis
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Rats, Nude
Genetic Therapy
Serpins
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
Laminin
Receptor Protein-Tyrosine Kinases
Epoxy Compounds
Niacinamide
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Dose-Response Relationship, Drug
Drug Combinations
Cornea
The transparent anterior portion of the fibrous coat of the eye consisting of five layers: stratified squamous CORNEAL EPITHELIUM; BOWMAN MEMBRANE; CORNEAL STROMA; DESCEMET MEMBRANE; and mesenchymal CORNEAL ENDOTHELIUM. It serves as the first refracting medium of the eye. It is structurally continuous with the SCLERA, avascular, receiving its nourishment by permeation through spaces between the lamellae, and is innervated by the ophthalmic division of the TRIGEMINAL NERVE via the ciliary nerves and those of the surrounding conjunctiva which together form plexuses. (Cline et al., Dictionary of Visual Science, 4th ed)
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Drugs, Investigational
Transfection
Gene Expression Regulation, Neoplastic
Blotting, Western
Culture Media, Conditioned
Cattle
Angiopoietin-2
An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Angiopoietin-1
Antibodies, Monoclonal, Humanized
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Spiro Compounds
Skin
Mice, Transgenic
Ischemia
Aminopeptidases
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Receptor, TIE-2
Carcinoma, Renal Cell
Fibrosarcoma
Pyridines
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Mice, Knockout
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Hindlimb
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Pyrimidines
Hypoxia-Inducible Factor 1, alpha Subunit
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Phosphorylation
Integrin alphaVbeta3
An integrin that binds to a variety of plasma and extracellular matrix proteins containing the conserved RGD amino acid sequence and modulates cell adhesion. Integrin alphavbeta3 is highly expressed in OSTEOCLASTS where it may play role in BONE RESORPTION. It is also abundant in vascular smooth muscle and endothelial cells, and in some tumor cells, where it is involved in angiogenesis and cell migration. Although often referred to as the vitronectin receptor there is more than one receptor for vitronectin (RECEPTORS, VITRONECTIN).
Dacarbazine
Antineoplastic Combined Chemotherapy Protocols
Immunoenzyme Techniques
Retinal Neovascularization
Disease Progression
Proteins
Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
Cell Survival
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Rats, Sprague-Dawley
Molecular Sequence Data
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Gene Expression
Treatment Outcome
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Pericytes
Unique slender cells with multiple processes extending along the capillary vessel axis and encircling the vascular wall, also called mural cells. Pericytes are imbedded in the BASEMENT MEMBRANE shared with the ENDOTHELIAL CELLS of the vessel. Pericytes are important in maintaining vessel integrity, angiogenesis, and vascular remodeling.
Drug Resistance, Neoplasm
Amino Acid Sequence
Membrane Proteins
DNA Primers
Carcinoma, Non-Small-Cell Lung
Angiopoietins
Up-Regulation
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Combined Modality Therapy
Proto-Oncogene Proteins c-akt
RNA, Small Interfering
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Hypoxia-Inducible Factor 1
Capillary Permeability
The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement.
Drug Administration Schedule
Melanoma, Experimental
Disease-Free Survival
Gene Expression Regulation
Thymidine Phosphorylase
Matrix Metalloproteinase Inhibitors
Neuropilin-1
Dimeric cell surface receptor involved in angiogenesis (NEOVASCULARIZATION, PHYSIOLOGICAL) and axonal guidance. Neuropilin-1 is a 140-kDa transmembrane protein that binds CLASS 3 SEMAPHORINS, and several other growth factors. Neuropilin-1 forms complexes with plexins or VEGF RECEPTORS, and binding affinity and specificity are determined by the composition of the neuropilin dimer and the identity of other receptors complexed with it. Neuropilin-1 is expressed in distinct patterns during neural development, complementary to those described for NEUROPILIN-2.
Models, Biological
Granulation Tissue
Down-Regulation
Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. (1/4006)
Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor gene p53 is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here, we investigated the antiangiogenic effect of the wild-type p53 (wt-p53) gene transfer on a human non-small cell lung cancer cell line. Mutant p53-expressing H226Br non-small cell lung cancer cells were transduced with the wt-p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semiquantitative reverse transcription-PCRs for the detection of altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system s.c. transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by s.c. inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor, and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1, resulting in reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wt-p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wt-p53 gene is antiangiogenic, which may explain, in part, the mechanism of the bystander effect induced by the wt-p53 gene transfer on adjacent tumor cells. (+info)Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. (2/4006)
Several angiogenesis inhibitors are fragments of larger proteins that are themselves not active as angiogenesis inhibitors. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is an angiogenesis inhibitor that exerts antitumor effects in vivo. In the present study, we examined whether the full-length calreticulin molecule shares the antiangiogenic and antitumor activities of vasostatin. Similar to vasostatin, calreticulin selectively inhibited endothelial cell proliferation in vitro, but not cells of other lineages, and suppressed angiogenesis in vivo. When inoculated into athymic mice, calreticulin inhibited Burkitt tumor growth comparably with vasostatin. Calreticulin lacking the N-terminal 1-120 amino acids inhibited endothelial cell proliferation in vitro and Burkitt tumor growth in vivo comparably with vasostatin. An internal calreticulin fragment encompassing amino acids 120-180 also inhibited endothelial cell proliferation in vitro and angiogenesis in vivo comparably with calreticulin and vasostatin. These results suggest that the antiangiogenic activities of vasostatin reside in a domain that is accessible from the full-length calreticulin molecule and localize to calreticulin N-terminal amino acids 120-180. Thus, calreticulin and calreticulin fragments are inhibitors of angiogenesis that directly target endothelial cells, inhibit angiogenesis, and suppress tumor growth. This information may be critical in designing targeted inhibitors of pathological angiogenesis that underlies cancer and other diseases. (+info)Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101. (3/4006)
We demonstrated in this study that inhibition of intra-hepatic growth of colon cancer by TAC-101 is mediated by inhibition of angiogenesis. In vitro experiments showed that TAC-101 inhibited the proliferation of murine hepatic sinusoidal endothelial (HSE) cells induced by coculture with murine colon 26-L5 (L5) cells. HSE cell proliferation was also enhanced by conditioned medium of L5 cells (CM-L5), and this enhancement of proliferation was abrogated by anti-vascular endothelial growth factor antibody. CM-L5 also induced in vitro tube formation of HSE cells on Matri-gel, and this activity of CM-L5 was abrogated by TAC-101 in a concentration-dependent manner. On the other hand, p.o. administration of TAC-101 inhibited tumor-induced angiogenesis in vivo and decreased the weights of L5 tumors in the mouse liver. Reverse transcriptase-PCR analysis using in vivo tumor tissue suggested that repression of vascular endothelial growth factor expression by TAC-101 was associated with the antiangiogenic activity. TAC-101 alone and 5-fluorouracil (5-FU)/D,L-leucovorin (LV) significantly inhibited the intrahepatic growth of L5 tumors (P = 0.002 and 0.001, respectively), whereas 5-FU alone did not (P = 0.088). When TAC-101 was administered with 5-FU/LV, marked enhancement of antitumor activity was observed (95% inhibition; P<0.001). This enhanced antitumor effect was also observed in experiments using Co-3 human colon adenocarcinoma. Concurrent treatment with TAC-101 and 5-FU/LV and sequential treatment with 5-FU/LV followed by TAC-101 resulted in significant augmentation of antitumor activity against Co-3 (overall P = 0.007 and 0.015, respectively). These findings indicate that TAC-101 inhibits tumor angiogenesis and suggest that it may be effective against hepatic metastasis of colon cancer. (+info)A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. (4/4006)
We conducted a Phase II clinical trial of the antiproliferative, antimetastatic, and antiangiogenic agent carboxyamido-triazole (CAI), using pharmacokinetic assessment to guide drug dosing. Fifteen patients who had stage D2 androgen-independent prostate cancer with soft tissue metastases were enrolled. Because CAI previously had been shown to decrease prostate-specific antigen secretion in vitro, this marker was not used to assess disease status. The dose of CAI used in this study was calculated so that plasma steady-state maximum concentrations between 2.0 and 5.0 microg/ml would be maintained. Following the initial dosage adjustment, 93% (14 of 15) of patients were within the predicted range. Fourteen of 15 patients were evaluable for response. All of the 14 evaluable patients demonstrated progressive disease at approximately 2 months. Twelve patients progressed by computed tomography and or bone scan at 2 months, whereas two patients demonstrated clinical progression at 1.5 and 2 months. One patient was removed from study at 6 weeks due to grade II peripheral neuropathy lasting >1 month. Although no clinical responses were noted, a 27.7% decrease in serum vascular endothelial growth factor concentration was observed. CAI does not possess clinical activity in patients with androgen-independent prostate cancer and soft tissue metastases. Pharmacokinetically guided dosing, although found to be feasible using a Bayesian approach, was not found to be of practical benefit. Although plasma CAI concentrations were maintained within the designated range, grade III toxicity requiring drug discontinuation was still observed. (+info)Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. (5/4006)
Theendothelial cell inhibitor endostatin (22 kDa) is part of the carboxyl-terminal globular domain of collagen XVIII and shows a widespread tissue distribution. Immunohistology of adult mouse tissues demonstrated a preferred localization in many vessel walls and some other basement membrane zones. A strong immunogold staining was observed across elastic fibers in the multiple elastic membranes of aorta and other large arteries. Staining was less strong along sparse elastic fibers of veins and almost none was observed in the walls of arterioles and capillaries. Strong evidence was also obtained for some intracellular and basement membrane associations. Immunogold double staining of elastic fibers showed a close colocalization of endostatin with fibulin-2, fibulin-1, and nidogen-2, but not with perlecan. Reasonable amounts of endostatin could be extracted from aorta and skin by EDTA, followed by detergents, with aorta being the richest source of the inhibitor identified so far. Solubilizations with collagenase and elastase were approximately fivefold less efficient. Immunoblots of aortic extracts detected major endostatin components of 22-25 kDa whereas skin extracts also contained some larger components. Solid-phase assays demonstrated distinct binding of recombinant mouse endostatin to the fibulins and nidogen-2, consistent with their tissue colocalization. Together, the data indicate several different ways for endostatin to be associated with the extracellular matrix, and its release may determine biological activation. This also defines a novel function for some elastic tissues. (+info)Antiangiogenic activity of prostate-specific antigen. (6/4006)
BACKGROUND: Measurement of serum levels of prostate-specific antigen (PSA) is widely used as a screening tool for prostate cancer. However, PSA is not prostate specific, having been detected in breast, lung, and uterine cancers. In one study, patients whose breast tumors had higher levels of PSA had a better prognosis than patients whose tumors had lower PSA levels. To test the hypothesis that PSA may have antiangiogenic properties, we evaluated the effects of PSA on endothelial cell proliferation, migration, and invasion, which are key steps in angiogenesis, the process by which tumors develop a blood supply. METHODS: To assess the antiproliferative effects of PSA, we treated bovine endothelial cells and human endothelial cell lines (HUVEC and HMVEC-d) with purified human PSA (0.1-10 microM) and then stimulated them with 10 ng/mL fibroblast growth factor-2 (FGF-2). Effects on FGF-2- or vascular endothelial growth factor (VEGF)-stimulated endothelial cell migration, invasion, and tube formation were measured by use of one cell line only (HUVEC). PSA was administered to mice at 9 microM for 11 consecutive days after intravenous inoculation of B16BL6 melanoma cells to assess its ability to inhibit the formation of lung colonies (i.e., metastatic tumors). RESULTS: PSA inhibited endothelial cell proliferation, migration, and invasion at IC(50) (i. e., the concentration at which inhibition was 50%) values ranging from 0.3-5 microM. In addition, PSA inhibited endothelial cell responses to both angiogenic stimulators tested, FGF-2 and VEGF. In a mouse model of metastatic disease, daily PSA treatment resulted in a 40% reduction in the mean number of lung tumor nodules compared with phosphate-buffered saline treatment (two-sided P =.003). CONCLUSION: To our knowledge, this is the first report that PSA may function in tumors as an endogenous antiangiogenic protein. This function may explain, in part, the naturally slow progression of prostate cancer. Our findings call into question various strategies to inhibit the expression of PSA in the treatment of prostate cancer. (+info)Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. (7/4006)
Recent evolutionary studies reveal that microorganisms including yeasts and fungi are more closely related to mammals than was previously appreciated. Possibly as a consequence, many natural-product toxins that have antimicrobial activity are also toxic to mammalian cells. While this makes it difficult to discover antifungal agents without toxic side effects, it also has enabled detailed studies of drug action in simple genetic model systems. We review here studies on the antifungal actions of antineoplasmic agents. Topics covered include the mechanisms of action of inhibitors of topoisomerases I and II; the immunosuppressants rapamycin, cyclosporin A, and FK506; the phosphatidylinositol 3-kinase inhibitor wortmannin; the angiogenesis inhibitors fumagillin and ovalicin; the HSP90 inhibitor geldanamycin; and agents that inhibit sphingolipid metabolism. In general, these natural products inhibit target proteins conserved from microorganisms to humans. These studies highlight the potential of microorganisms as screening tools to elucidate the mechanisms of action of novel pharmacological agents with unique effects against specific mammalian cell types, including neoplastic cells. In addition, this analysis suggests that antineoplastic agents and derivatives might find novel indications in the treatment of fungal infections, for which few agents are presently available, toxicity remains a serious concern, and drug resistance is emerging. (+info)Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. (8/4006)
The effects of the angiogenic inhibitors endostatin, angiostatin, and TNP-470 on tumor growth dynamics are experimentally and theoretically investigated. On the basis of the data, we pose a quantitative theory for tumor growth under angiogenic stimulator/inhibitor control that is both explanatory and clinically implementable. Our analysis offers a ranking of the relative effectiveness of these inhibitors. Additionally, it reveals the existence of an ultimate limitation to tumor size under angiogenic control, where opposing angiogenic stimuli come into dynamic balance, which can be modulated by antiangiogenic therapy. The competitive influences of angiogenically driven growth and inhibition underlying this framework may have ramifications for tissue size regulation in general. (+info)
Angiogenesis Inhibitors Research - Page 433 - All about Angiogenesis Inhibitors Research
Marmesin is a novel angiogenesis inhibitor: Regulatory effect and molecular mechanism on endothelial cell fate and angiogenesis...
The Antiangiogenic Compound Aeroplysinin-1 Induces Apoptosis in Endothelial Cells by Activating the Mitochondrial Pathway - pdf...
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells | Cancer Research
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine...
Anti-Angiogenic Drug Much More Effective When Immune System Primed Against Cancer
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma - Tabular View...
Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma<...
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? | Breast Cancer Research | Full...
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy | Science
A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs | Clinical Cancer...
Download Free Biology Books: Antiangiogenic Agents in Cancer Therapy (Cancer Drug Discovery and Development)
ORBi: Browsing ORBi
Mesenchymal stromal cell (MSC)- based control of angiogenesis and inflammation in cartilage formation - edoc
Targeting Bone Marrow Small Non-coding RNAs in Cancer
Angiogenesis inhibitor improves brain tumor survival by redu... ( The beneficial effects of anti-angio...)
Brad St. Croix, Ph.D. | Center for Cancer Research
Plus it
JCI -
Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis
Various miRNAs predict the effect of anti-angiogenic agents on renal cancer
JCI -
E-letters
Phase I Study of Gemcitabine With Antiangiogenic Vaccine [angiogenesis inhibitor vaccine] Therapy Using Epitope Peptide...
Figures and Graphics: Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with...
Journal of Current Glaucoma Practice
The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from...
Anti-Angiogenic Therapy and Cardiovascular Diseases - Drug Discovery and Development
KAKEN - Research Projects | Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF. ...
JCI -
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A
DSpace at EWHA: Effect of Retinoic Acid on Renal Development in Newborn Mice Treated with an Angiogenesis Inhibitor
Exercise sub-cluster 33
Avastin Added to Chemo Helps Women With Advanced Bre... ( Anti-angiogenesis drug prolonged prog...)
A Quantitative Approach to Predict Differential Effects of Anti-VEGF Treatment on Diffuse and Focal Leakage in Patients with...
The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and...
Imaging studies may predict tumor response to antiangiogenic drugs - ONA
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity<...
Episode 38: Systemic Effects of Anti-VEGF Therapy - Eyetube
Value of usefulness of diffuse optical spectroscopic imaging for monitoring efficacy of aingle agent bevacizumab followed by...
Clinical Trials Register
WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domaincontaining...
Click to print
Plus it
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. | Medic Debate
Interference with the activity of TSP-1 and its antiang | Open-i
Antiangiogenic therapies in colorectal cancer | springermedizin.at
Plus it
Angiogenesis Inhibitors
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration<...
Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments | Bentham Science
Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to...
A small hypoxia signature predicts response to neoadjuvant bevacizumab treatment - GBG
Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma...
Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma...
Serum Eyedrops Antagonize the Anti(lymph)angiogenic Effects of Bevacizumab In Vitro and In Vivo | IOVS | ARVO Journals
Anti-angiogenic therapy for uveal melanoma-more haste, less speed | British Journal of Ophthalmology
Cancers | Free Full-Text | Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies
The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing.
Temodar avastin - Avastin online
Plus it
Citation tools | Molecular Cancer Therapeutics
Muscarinic (M3) Receptors | Discovery of Novel Antigiardiasis Drug
Two-dimensional models of tumour angiogenesis and anti-angiogenesis strategies : Mathematical Medicine and Biology: A Journal...
Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. - Department of Pharmacology
Avastin/Paclitaxel Gets Accelerated Approval for Advanced Breast Ca
Neoadjuvant Bevacizumab May Benefit Subset of Breast Cancer Patients | Cancer Network
ORBi: Browsing ORBi
Genentech Eases Stance on Bevacizumab (Avastin) for Macular Degeneration
Ethanol, RA and thalidomide treatments lead to major gl | Open-i
266714 | Stanford Health Care
RGS5 | BRAF mutants Targeted inhibition of metastatic melanoma
Avastin (bevacizumab) Basics, Side Effects & Reviews - Iodine.com
Almac Discovery Announces Licensing of ALM201 to Shin Poong for Development and Marketing in South Korea | SelectScience
Enzyme helps prepare lung tissue for metastatic development
Anti-Angiogenesis - UNM Comprehensive Cancer Center
Plus it
Angiogenesis inhibitor - Wikipedia
Patent US7771706 - Method for monitoring protein translation - Google Patents
Angiogenesis Inhibitors | Johns Hopkins Medicine Health Library
Angiogenesis inhibition | Hypertension
Anti-VEGF Treatment for Non-AMD Disease - Retina Consultants
Brain-specific angiogenesis inhibitor 2
... is a protein that in humans is encoded by the BAI2 gene. It is a member of the adhesion ... BAI1, a p53-target gene, encodes brain-specific angiogenesis inhibitor, a seven-span transmembrane protein and is thought to be ... 2002). "Expression of brain-specific angiogenesis inhibitor 2 (BAI2) in normal and ischemic brain: involvement of BAI2 in the ... "Entrez Gene: BAI2 brain-specific angiogenesis inhibitor 2". Stacey, edited by Simon Yona, Martin (2010). Adhesion-GPCRs : ...
Angiogenesis inhibitor
See [1] and [2] Angiogenesis Inhibitors for Cancer - from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors for ... An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis ... Thus angiogenesis inhibitors have been closely studied for possible cancer treatment. Angiogenesis inhibitors were once thought ... 23 June 2009 Angiogenesis Inhibitors in the Treatment of Cancer - from the National Cancer Institute Angiogenesis+Inhibitors at ...
Cartilage-derived angiogenesis inhibitor
A cartilage-derived angiogenesis inhibitor is an angiogenesis inhibitor produced from cartilage. Examples include the peptide ... v t e (Angiogenesis inhibitors, All stub articles, Biochemistry stubs). ... a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer". ... March 2004). "Suppression of T cell responses by chondromodulin I, a cartilage-derived angiogenesis inhibitory factor: ...
Brain-specific angiogenesis inhibitor
... 1 Brain-specific angiogenesis inhibitor 2 Brain-specific angiogenesis inhibitor 3 ... Brain-specific angiogenesis inhibitors are G-protein coupled receptors belonging to the class B secretin subfamily. Members ... novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)". Cytogenet. Cell Genet. 79 (1-2): 103-8. doi:10.1159/ ...
Brain-specific angiogenesis inhibitor 3
... is a protein that in humans is encoded by the BAI3 gene. BAI1, a p53-target gene, ... "Entrez Gene: BAI3 brain-specific angiogenesis inhibitor 3". Lanoue, V; Usardi, A; Sigoillot, S M; Talleur, M; Iyer, K; Mariani ... encodes brain-specific angiogenesis inhibitor, a seven-span transmembrane protein and is thought to be a member of the secretin ... novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)". Cytogenetics and Cell Genetics. 79 (1-2): 103-108. ...
Brain-specific angiogenesis inhibitor 1
... an inhibitor of angiogenesis and a growth suppressor of glioblastomas. Brain-specific angiogenesis inhibitor 1 has been shown ... Brain-specific angiogenesis inhibitor 1 is a protein that in humans is encoded by the BAI1 gene. It is a member of the adhesion ... "Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis". ... Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under ...
Medication-related osteonecrosis of the jaw
Angiogenesis inhibitors interfere with blood vessel formation by interfering with the angiogenesis signalling cascade. They are ... "Angiogenesis Inhibitors". National Cancer Institute. May 2018. Retrieved 2018-02-19. Rosella D, Papi P, Giardino R, Cicalini E ... Another suggested factor is inhibition of angiogenesis due to bisphosphonates; this effect remains uncertain. Several studies ... March 2005). "Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients". Journal of ...
Tumstatin
Angiogenesis Angiogenesis inhibitor Apoptosis Endostatin Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R (April ... Tumstatin is a cell-specific inhibitor for protein synthesis and therefore affects angiogenesis, which occurs at the protein ... Nyberg P, Xie L, Kalluri R (May 2005). "Endogenous inhibitors of angiogenesis". Cancer Res. 65 (10): 3967-79. doi:10.1158/0008- ... July 2004). "Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic ...
David Gorski
This research has been used in anti-tumor therapeutic research, including an observation that angiogenesis inhibitors enhanced ... "Clinical translation of angiogenesis inhibitors". Nature Reviews Cancer. 2 (10): 727-739. doi:10.1038/nrc905. PMID 12360276. ... characterizing the effects of angiogenesis inhibitors on the effectiveness of anti-tumor therapies, has been cited over 900 ... Chen, Yun; Gorski, David H. (1 February 2008). "Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates ...
Immunomodulatory imide drug
Inhibition of TNF-α is not the mechanism of thalidomide's inhibition of angiogenesis since numerous other TNF-α inhibitors do ... D'Amato RJ, Loughnan MS, Flynn E, Folkman J (April 1994). "Thalidomide is an inhibitor of angiogenesis". Proc. Natl. Acad. Sci ... Additionally, these analogs are more potent inhibitors of angiogenesis than thalidomide. As well, the amino-thalidomide and ... "Angiogenesis inhibitors derived from thalidomide". Bioorganic & Medicinal Chemistry Letters. 15 (24): 5509-5513. doi:10.1016/j. ...
ABT-510
Webarchive template wayback links, Angiogenesis inhibitors). ...
Sharks Don't Get Cancer
Lee, A; Langer, R (16 September 1983). "Shark cartilage contains inhibitors of tumor angiogenesis". Science. 221 (4616): 1185-7 ...
Matrix metalloproteinase inhibitor
There are also cartilage-derived angiogenesis inhibitors. Exogenous matrix metalloproteinase inhibitors were developed as ... Drug discovery and development of MMP inhibitors Coussens, L. M. (2002). "Matrix Metalloproteinase Inhibitors and Cancer-- ... A matrix metalloproteinase inhibitor (MMPI) inhibits matrix metalloproteinases. As they inhibit cell migration they have ... Noel Vinay Thomas; Se Kwon Kim (2010). "Metalloproteinase Inhibitors Stts and Scope from Marine Organisms". Biochemistry ...
Tumor-associated endothelial cell
Various angiogenesis inhibitors have been developed to interfere with different steps in the process. Bevacizumab (Avastin) is ... Sorafenib and sutinib are additional angiogenesis inhibitors that bind and block receptors on endothelial cells that have ... Cook, Kristina M.; Figg, William D. (2010-07-01). "Angiogenesis inhibitors: current strategies and future prospects". CA: A ... Shih, Ted; Lindley, Celeste (2006-11-01). "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies". ...
Diabetic retinopathy
2017, "Risk factors". Ryeom S, Folkman J (March 2009). "Role of endogenous angiogenesis inhibitors in Down syndrome". The ...
Endostatin
Among anti-angiogenesis inhibitors, endostatin has a wide range of anti-cancer spectrum targets, increasing its significance ... Endogenous inhibitors of angiogenesis are present in both normal tissue and cancerous tissue. Overall, endostatin down ... Endostatin is a broad-spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such ... Hohenester, E.; Sasaki, T.; Olsen, B.R.; Timpl, R. (1998). "Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A ...
Borrelidin
"Borrelidin is an angiogenesis inhibitor; disruption of angiogenic capillary vessels in a rat aorta matrix culture model". The ... "Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tü4055: cluster analysis and assignment of ... "Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tü4055: insights into nitrile formation". ... First discovered in 1949 from Streptomyces rochei, Borrelidin shows antibacterial activity by acting as an inhibitor of ...
Thrombospondin
Sorbera LA, Bayes M (2005). "ABT-510: oncolytic angiogenesis inhibitor". Drugs of the Future. Prous Science. 30 (11): 1081-6. ... April 2005). "Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization ... Since tumors overexpressing TSP-1 typically grow slower, exhibit less angiogenesis, and have fewer metastases, TSP1 is an ... functions for TSP-1 have been found in multiple biological processes including angiogenesis, apoptosis, activation of TGF-beta ...
Angiozyme
It belongs to the families of drugs called VEGF receptor and angiogenesis inhibitors. Preliminary tests have demonstrated that ... Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141-146. doi ... It may prevent the growth of blood vessels from surrounding tissue to the tumor, i.e., angiogenesis. ... Angiogenesis has no significant side effects. It is also known as RPI.4610. "Ribozyme Pharmaceuticals Going Into Clinical ...
Marimastat
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo ... This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in ... It acted as a broad-spectrum matrix metalloproteinase inhibitor. Marimastat performed poorly in clinical trials, and ... "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers ...
Thalidomide
... who was looking for angiogenesis inhibitors, discovered in 1994 that thalidomide inhibited angiogenesis and was effective in ... D'Amato RJ, Loughnan MS, Flynn E, Folkman J (April 1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the ... Ribatti D (2008). "Judah Folkman, a pioneer in the study of angiogenesis". Angiogenesis. 11 (1): 3-10. doi:10.1007/s10456-008- ... As of 2015[update], the main theories were inhibition of the process of angiogenesis, its inhibition of cereblon, a ubiquitin ...
Judah Folkman
... was looking for angiogenesis inhibitors, and discovered that thalidomide inhibited angiogenesis in 1994. Around that time, the ... In 2004, the first angiogenesis inhibitor, bevacizumab (Avastin), was approved by the FDA, as a treatment for colon cancer. It ... D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the National ... Ribatti D (2008). "Judah Folkman, a pioneer in the study of angiogenesis". Angiogenesis. 11 (1): 3-10. doi:10.1007/s10456-008- ...
Pomalidomide
D'Amato RJ, Loughnan MS, Flynn E, Folkman J (April 1994). "Thalidomide is an inhibitor of angiogenesis". Proceedings of the ... since potent TNF inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth or angiogenesis. ... Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, ... April 2002). "S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice". Cancer Research ...
Causes of cancer pain
... angiogenesis inhibitors like bevacizumab, known to sometimes cause bone pain; and surgery, which may produce post-operative ... Aromatase inhibitors can cause diffuse muscle and joint pain and stiffness, and may increase the likelihood of osteoporosis and ... the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin. Whether CIPN ...
Cancer pain
... angiogenesis inhibitors like bevacizumab, known to sometimes cause bone pain; surgery, which may produce post-operative pain, ... non-steroidal anti-inflammatory drugs or COX-2 inhibitors. Then, if complete pain relief is not achieved or disease progression ...
TIMP2
Stetler-Stevenson WG, Seo DW (2005). "TIMP-2: an endogenous inhibitor of angiogenesis". Trends in Molecular Medicine. 11 (3): ... Tissue inhibitor of metalloproteinases 2 (TIMP2) is a gene and a corresponding protein. The gene is a member of the TIMP gene ... Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, Cao J (January 1998). "Tissue inhibitor ... Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM (June 1997). "Specific, high affinity binding of tissue inhibitor of ...
Withaferin A
2004). "Withaferin A is a potent inhibitor of angiogenesis". Angiogenesis. 7 (2): 115-122. doi:10.1007/s10456-004-1026-3. PMID ... It is a potent inhibitor of angiogenesis. Anti-angiogenic and anti-tumor activity of withaferin A is due to the inhibition of ... "A Novel MMP-2 Inhibitor 3-azidowithaferin A (3-azidoWA) Abrogates Cancer Cell Invasion and Angiogenesis by Modulating ... 2007). "The tumor inhibitor and antiangiogenic agent Withaferin A targets the intermediate filament protein Vimentin". ...
Secretin receptor family
Brain-specific angiogenesis inhibitor InterPro: IPR008077 BAI1; BAI2; BAI3 CD97 antigen InterPro: IPR003056 CD97 EMR hormone ... calcium-independent receptors for latrotoxin and brain-specific angiogenesis inhibitor receptors amongst others. They are ...
Yihai Cao
Cao participated in the discovery of angiostatin, an endogenous angiogenesis inhibitor, in Judah Folkman ́s Laboratory. He ... Cao's laboratory discovered catechins in green tea as oral angiogenesis inhibitors. They also discovered several ... is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice". The Journal of Experimental Medicine ... a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma". Cell. 79 (2): 315-328. ...
Steven Libutti
A variety of inhibitors of tumor angiogenesis are being actively studied. These include both recombinant proteins derived from ... which appear to play a role in the control of endothelial cell responses to angiogenesis inhibitors. They are also using ... The process of new vessel development within the tumor is termed angiogenesis and is required for tumors to grow larger than a ... Libutti's work on the study of tumor angiogenesis and the tumor microenvironment has led to novel approaches for the treatment ...
Prostaglandin-endoperoxide synthase 2
Non-substrate FAs can potentiate or attenuate PTGS (COX) inhibitors depending on the fatty acid and whether the inhibitor binds ... The overexpression of PTGS2 (COX-2) along with increased angiogenesis and SLC2A1 (GLUT-1) expression is significantly ... PTGSs are targets for NSAIDs and PTGS2 (COX-2) specific inhibitors called coxibs. PTGS-2 is a sequence homodimer. Each monomer ... Substrate and non-substrate fatty acid (FAs) and some PTGS (COX) inhibitors (e.g. naproxen) preferentially bind to the PTGS ( ...
Proto-oncogene tyrosine-protein kinase Src
HSP90 inhibitor NVP-BEP800 has been described to affect stability of Src tyrosine kinase and growth of T-cell and B-cell acute ... Since the activation of c-Src leads to the promotion of survival, angiogenesis, proliferation and invasion pathways, the ... Other tyrosine kinase inhibitor drugs that are in clinical trials include bosutinib, bafetinib, AZD-0530, XLl-999, KX01 and ... When the primary prostate cells are treated with KRX-123, which is an inhibitor of Lyn, the cells in vitro were reduced in ...
Napoleone Ferrara
These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), ... Napoleone Ferrara discusses Avastin and the future of anti-angiogenesis therapy, ScienceDirect. Strauss, Evelyn. "2010 Winners ... He is presently focusing on investigating mechanisms of tumor angiogenesis alternative to VEGF, in particular the role of ... where he will continue cancer drug research targeting angiogenesis.[citation needed] ...
Interferon
Chang HW, Watson JC, Jacobs BL (June 1992). "The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, ... Interferons can also suppress angiogenesis by down regulation of angiogenic stimuli deriving from tumor cells. They also ... Ho M, Enders JF (March 1959). "An Inhibitor of Viral Activity Appearing in Infected Cell Cultures". Proceedings of the National ... Such suppression causes a decrease in tumor angiogenesis, a decrease in its vascularization and subsequent growth inhibition. ...
Axel Ullrich
Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in ... In the early 1990s, Ullrich and his team identified the signaling system involved in regulating tumor angiogenesis, the growth ... which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets ...
Thromboxane-A synthase
Thromboxane synthase inhibitors are used as antiplatelet drugs. Ifetroban is a potent and selective thromboxane receptor ... angiogenesis, and metastasis. Thromboxane synthesis Eicosanoid synthesis Prostanoid 12-Hydroxyheptadecatrienoic acid GRCh38: ... Picotamide has activity both as a thromboxane synthase inhibitor and as a thromboxane receptor antagonist. The human ...
Collagen, type IV, alpha 2
The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth. Like the other ... Kalluri R, Sukhatme VP (2000). "Fibrosis and angiogenesis". Curr. Opin. Nephrol. Hypertens. 9 (4): 413-8. doi:10.1097/00041552- ...
BMP binding endothelial regulator
"Human Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins". Biochemical and Biophysical Research Communications ... "BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis". Circulation Research ...
HU-336
Angiogenesis inhibitors, HU cannabinoids). ... It inhibits angiogenesis by directly inducing apoptosis of ... HU-336 is a strongly antiangiogenic compound, significantly inhibiting angiogenesis at concentrations as low as 300 nM. ... "A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells". Molecular Pharmacology. 70 (1): 51-9. doi ...
Computed tomography laser mammography
... or angiogenesis. The area of angiogenesis is generally much larger than the tumor itself, and hence CTLM can detect small ... 23-95% experience discomfort, and pain is a significant inhibitor to re-attending screenings. CTLM was therefore developed as ... This medical imaging technique uses laser energy in the near infrared region of the spectrum, to detect angiogenesis in the ... In new forming tumors, the blood flow increases and the CTLM then looks for high hemoglobin concentration (angiogenesis) in the ...
Prostate cancer
Also in trials for CRPC are : checkpoint inhibitor ipilimumab, CYP17 inhibitor galeterone (TOK-001), and immunotherapy PROSTVAC ... angiogenesis and metastasis". Glycobiology. 24 (10): 899-906. doi:10.1093/glycob/cwu055. PMID 24939371. Alimirah F, Chen J, ... While the commonly used inhibitors produced strong cytotoxicity, notably, zileuton, the only commercialized 5-LOX inhibitor, ... X-linked inhibitor of apoptosis (XIAP) is hypothesized to promote cancer cell survival and growth, the Macrophage inhibitory ...
Philip Lazarovici
Lecht, Shimon; Haroutiunian, Simon; Hoffman, Amnon; Lazarovici, Philip (2007). "Rasagiline - a novel MAO B inhibitor in ... Promotes Angiogenesis in the Quail Chorioallantoic Membrane". Endothelium. 13 (1): 51-59. doi:10.1080/10623320600669053. PMID ... "Nerve Growth Factor-Induced Angiogenesis: 1. Endothelial Cell Tube Formation Assay". Neurotrophic Factors. Methods in Molecular ...
Polycystin 2
Li Q, Shen PY, Wu G, Chen XZ (January 2003). "Polycystin-2 interacts with troponin I, an angiogenesis inhibitor". Biochemistry ...
Prinomastat
... (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, ... MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. ... a matrix metalloprotease inhibitor" (PDF). Clinical Cancer Research. 10 (3): 909-15. doi:10.1158/1078-0432.CCR-0981-3. PMID ... "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer" (PDF). Journal of Clinical ...
Tasquinimod
... reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial ... Tasquinimod is a novel small-molecule inhibitor that targets the tumor microenvironment by controlling the accumulation and ... Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and ...
Hanoch Senderowitz
Inhibitors Based on Uridine 5′-Pα,α-Dithiophosphate Analogues". Journal of Medicinal Chemistry. 61 (9): 3939-3951. doi:10.1021/ ... Anti-Angiogenesis Drug Discovery and Development. pp. 16-45. doi:10.2174/9781681081557116030004. ISBN 9781681081557. Yosipof, ... "Novel inhibitors of leukocyte transendothelial migration". Bioorganic Chemistry. 92: 103250. doi:10.1016/j.bioorg.2019.103250. ...
Cancer
Angiogenesis inhibitors were once incorrectly thought to have potential as a "silver bullet" treatment applicable to many types ... Angiogenesis inhibitors and other cancer therapeutics are used in combination to reduce cancer morbidity and mortality. ... Aspirin has been found to reduce the risk of death from cancer by about 7%. COX-2 inhibitors may decrease the rate of polyp ... Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS (April 2008). Wilt TJ (ed.). "Five-alpha-reductase Inhibitors for ...
Pharmacoepigenetics
DNA methyltranferase inhibitors are usually used at a low level due to their lack of specificity and toxic effects on normal ... and encouraging angiogenesis and myogenesis in embryonic cells. One of the common characteristics of various types of cancer is ... HDAC inhibitors are also being used, due to the changes in histone acetylation and the increased HDACs observed. While the ... BET inhibitors have been able to prevent successful interaction between BET proteins and acetylated histones. Using a BET ...
MECOM
It has been observed that it not only induces apoptosis but can also inhibit the cell cycle, and has marked anti-angiogenesis ... TGF-β signaling induces transcription of the cyclin-dependent kinase (CDK) inhibitors p15Ink4B or p21Cip1, which, as a ... HSCs secrete angiopoietin, and its receptor molecule Tie2 has been implicated in angiogenesis of tumors in both humans and mice ... Upregulation of Tie2 has been shown to occur under hypoxic conditions, and to increase angiogenesis when coinjected with tumor ...
EPH receptor A2
It may be implicated in BRAF mutated melanomas becoming resistant to BRAF-inhibitors and MEK inhibitors. It is also the ... in TNF-alpha-induced angiogenesis". Science. 268 (5210): 567-9. Bibcode:1995Sci...268..567P. doi:10.1126/science.7536959. PMID ... receptor by which Kaposi sarcoma-associated herpesvirus (KSHV) enters host cells; small molecule inhibitors of EphA2 have shown ...
Joachim Drevs
Drevs has conducted research on the topic of angiogenesis, and was present during the making of a new group of medications for ... Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary ... a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the Anatomy of the Tumor Vascular Bed ... an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors. Joachim Drevs, Patrizia ...
Ubiquitin
SKP2 targets p27Kip-1, an inhibitor of cyclin-dependent kinases (CDKs). CDKs2/4 partner with the cyclins E/D, respectively, ... HIF activates downstream targets such as the vascular endothelial growth factor (VEGF), promoting angiogenesis. Mutations in ... Dou QP, Li B (August 1999). "Proteasome inhibitors as potential novel anticancer agents". Drug Resistance Updates. 2 (4): 215- ... ubiquitin/proteasome pathway in oncogenic processes was observed due to the high antitumor activity of proteasome inhibitors. ...
MicroRNA
MiR-712 targets tissue inhibitor of metalloproteinases 3 (TIMP3). TIMPs normally regulate activity of matrix metalloproteinases ... angiogenesis, and apoptotic pathway. The vital role of miRNAs in gene expression is significant to addiction, specifically ...
Platelet-derived growth factor
... factor receptor atheroma platelet involvement in smooth muscle proliferation Withaferin A potent inhibitor of angiogenesis ... Wortmannin is a PI3K-specific inhibitor, and treatment of cells with Wortmannin in combination with PDGF resulted in enhanced ... PDGF plays a role in embryonic development, cell proliferation, cell migration, and angiogenesis. Over-expression of PDGF has ... which are active in angiogenesis and endothelial cell growth, and placenta growth factor (PlGF) which is also active in ...
Ofranergene obadenovec
Angiogenesis inhibitors). ...
AXL receptor tyrosine kinase
Axl is an inhibitor of the innate immune response. The function of activated AXL in normal tissues includes the efficient ... angiogenesis, and immune modulation. AXL has been implicated as a cancer driver and correlated with poor survival in numerous ... Additionally, an oral AXL inhibitor (TP-0903) is expected to enter Phase 1 clinical trial in November 2016 (in advanced solid ... Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007). "TAM receptors are pleiotropic inhibitors of the innate immune ...
Cathelicidin
Furthermore, it induces angiogenesis and regulates apoptosis. These processes are dysregulated during tumor development, and ... Ritonja A, Kopitar M, Jerala R, Turk V (September 1989). "Primary structure of a new cysteine proteinase inhibitor from pig ... The name cathelin itself is coined from cathepsin L inhibitor in 1989. The general rule of the mechanism triggering ... The cathelicidin family shares primary sequence homology with the cystatin family of cysteine proteinase inhibitors, although ...
Ranibizumab
Although there is a theoretical risk for arterial thromboembolic events in people receiving VEGF-inhibitors by intravitreal ... Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, a mechanism ...
AKR1B1
Adapting AR inhibitors could as well prevent sepsis complications, prevent angiogenesis, ameliorate mild or asymptomatic ... Fatmawati S, Ersam T, Yu H, Zhang C, Jin F, Shimizu K (September 2014). "20(S)-Ginsenoside Rh2 as aldose reductase inhibitor ... Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS (2016-01-01). "Updates on Aldose Reductase Inhibitors for Management of ... Gupta S, Singh N, Jaggi AS (March 2014). "Alkaloids as aldose reductase inhibitors, with special reference to berberine". ...
Reports About Angiogenesis inhibitors - KaloramaInformation
British Library EThOS: The early clinical development of the angiogenesis inhibitors SU5416 and SU06668
Molecular Vision: Inhibition of choroidal neovascularization
by topical application of angiogenesis inhibitor vasostatin
Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. Shwu-Jiuan Sheu,1,2 ... A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 2002; 9:1207-13. [PMID: 12215887] ... Vasostatin (VS), the N-terminal domain (amino acids 1-180) of calreticulin, is a potent angiogenesis inhibitor isolated from ... an endogenous angiogenesis inhibitor, on CNV. Methods: Anti-angiogenic activity of VS was evaluated in vitro by migration and ...
Nephropathy following administration of angiogenesis inhibitors | Nefrología
Nephropathy following administration of angiogenesis inhibitors Nefropatía tras la administración de inhibidores de la ... Angiogenesis has an important role in metastasis development. In recent years, the vascular endothelial growth factor (VEGF) ... Various studies have shown that the anti-VEGF monoclonal antibody, bevacizumab, can reduce angiogenesis and inhibit solid ... has become one of the main objectives in treating tumour-induced angiogenesis. ...
Non-Hodgkin Lymphoma (NHL) Medication: Cytotoxic agents, Antineoplastic Agents, Histone Deacetylase Inhibitors, Antineoplastics...
Antineoplastics, Angiogenesis Inhibitor. Class Summary. These agents antagonize or inhibit the development of new blood vessels ... Antineoplastics, PI3K Inhibitors. Class Summary. This drug class inhibits one or more of the phosphoinositide 3-kinase enzymes ... Antineoplastic Agents, Proteasome Inhibitors. Class Summary. Agents in this class may cause cell-cycle arrest and apoptosis. ... Antineoplastic Agents, mTOR Kinase Inhibitors. Class Summary. Agents in this class halt the cell cycle at the G1 phase in tumor ...
Angiogenesis Inhibitors
Browsing Mathematics & Statistics Department by Subject "Angiogenesis inhibitors"
Angiogenesis - PD-1 inhibitor inducing Resistance in Melanoma
E: Representative Sytox green extracellular DNA fluorescence and phase-contrast images of neutrophils used for NET quantification. IRI. Moreover, the rAAV8-TIMP-1 vector therapy enhanced significantly the 7-day survival rate of without significant toxicity or immune response.21, 22 Materials and Methods Mice and Model of Hepatic IRI C57BL/6 mice and C57BL/6 mice carrying the null allele (B6.129S4-biodistribution…. ...
Cancer: MedlinePlus
Research Profile Listing | Yale School of Medicine
An Update on Gastroenteropancreatic Neuroendocrine Tumors
Angiogenesis Inhibitors. Angiogenesis inhibitors can suppress the VEGF receptor (VEGFR) or neutralize circulating VEGF. The ... While everolimus and sunitinib are active in pNETs, the role of mTOR and angiogenesis inhibitors in carcinoid tumors remains ... mTOR Inhibitors. The mTOR inhibitor everolimus has been extensively studied in GEP-NETs. The phase II RADIANT 1 trial compared ... Newer drugs, targeting angiogenesis and mammalian target of rapamycin (mTOR) pathways, have been approved for progressive ...
Human BAI1(Brain Specific Angiogenesis Inhibitor 1) ELISA Kit - ELISA Kits
Human BAI1(Brain Specific Angiogenesis Inhibitor 1) ELISA Kit. Human BAI1(Brain Specific Angiogenesis Inhibitor 1) ELISA Kit. ... Human Brain Specific Angiogenesis Inhibitor 1 (BAI1) ELISA Kit. SEC346Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate ... Human Brain Specific Angiogenesis Inhibitor 3 (BAI3) ELISA Kit. SEF233Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate ... Human Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 1 (BAIAP2L1) ELISA Kit. ...
Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents
Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in...
Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in ... The development of new blood vessels (angiogenesis) is necessary to sustain the growth of primary tumor as well as a process of ... Drugs that inhibit angiogenesis could offer a treatment that is complementary to traditional chemotherapy. Chemotherapy ...
Osteochondral plate angiogenesis: a new treatment target in osteoarthritis
The mechanisms underlying cartilage angiogenesis in osteoarthritis are unclear but may involve hypertrophic chondrocyte ... Angiogenesis Inhibitors / therapeutic use * Cartilage, Articular / blood supply* * Cell Differentiation / physiology * ... Osteochondral plate angiogenesis: a new treatment target in osteoarthritis Joint Bone Spine. 2011 Mar;78(2):144-9. doi: 10.1016 ... Active research is under way to identify the factors involved in cartilage angiogenesis. Here, we discuss the ...
Angiogenesis is a simple biological process that's regulated by an excellent - PARG inhibitors in cancer therapy
Pathological Angiogenesis Insufficient angiogenesis Both angiogenesis insufficiency aswell as excess can result in several ... Angiogenesis is a simple biological process thats regulated by an excellent stability between pro- and antiangiogenic ... Sponge Implant Versions: Angiogenesis is generally analyzed from the subcutaneous implantation of artificial sponges in pets. ... Benefits of versions include the capability to study the average person methods of angiogenesis, the chance to control the ...
Bevacizumab In Hereditary Hemorrhagic Telangiectasia - Full Text View - ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration ...
DeCS - Termos Novos
Study shows medical schools lack end-of-life training - Harvard Gazette
Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor<...
Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. ... Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor ... Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor ... Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor ...
Prostate Cancer | Department of Urology | SUNY Upstate Medical University
... www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet. Accessed October 9, 2020. ... For example, daily aspirin therapy and 5-alpha reductase inhibitors may reduce your risk of prostate cancer. ... Angiogenesis inhibitors. National Cancer Institute website. Available at: https:// ...
Targeted Therapy for Cancer - NCI
The tumor sends signals that start angiogenesis. Some targeted therapies called angiogenesis inhibitors interfere with these ... Learn more about angiogenesis inhibitors. Targeted Therapy Improves Survival for Metastatic "HER2-Low" Breast Cancer. Enhertu ... tumors need to form new blood vessels in a process called angiogenesis. ...
Hibiscus sabdariffa | GreenMedInfo | Substance | Natural Medicine
Alpha-amylase inhibitor. 1. 1. Alpha-glucosidase inhibitor 1. 1. Angiogenesis Inhibitors. 1. 1. ... Pharmacological Actions : Anti-Inflammatory Agents, Interleukin-6 Downregulation, Tumor Necrosis Factor (TNF) Alpha Inhibitor ... Pharmacological Actions : Anti-metastatic, Antioxidants, Apoptotic, Matrix metalloproteinase-9 (MMP-9) inhibitor ... Anthocyanin-rich extracts from Hibiscus sabdariffa inhibited angiogenesis in time and concentration-dependent manner.Jan 31, ...
University of Glasgow - Postgraduate research students - Stephen Dobbin
Metastasis: a question of life or death | Nature Reviews Cancer
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315 ... Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997). ... Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in ... Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer ...
Marine Drugs | Special Issue : Marine Compounds as Protein Kinase Inhibitors
Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and ... Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and ... This review will first provide an overview of the current marine-derived angiogenesis inhibitors based on their primary targets ... Marine Derived Hamacanthins as Lead for the Development of Novel PDGFRβ Protein Kinase Inhibitors by Boris Pinchuk ...
Cancer and Vasculopathy: Old and New Treatments - American College of Cardiology
Keywords: Alkylating Agents, Angiogenesis Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Anthracyclines, Antibodies, ... Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence ... Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A ... newer generation BCR-ABL kinase inhibitors, and the multi-targeted tyrosine kinase inhibitors may also be related to venous ...
Effect of Non-Anticoagulant N-Desulfated Heparin on Basic Fibroblast Growth Factor Expression, Angiogenesis, and Metastasis of...
... tumor angiogenesis and metastasis of gastric carcinoma. ,i,Methods,/i,. Human gastric cancer SGC-7901 tissues were ... desulfated heparin can inhibit the metastasis of gastric cancer through inhibiting tumor bFGF expression and tumor angiogenesis ... During tumor-associated angiogenesis, the balance of angiogenesis stimulators and inhibitors is tipped in favor of angiogenesis ... are elicited by various highly regulated angiogenesis stimulators and inhibitors [1]. Angiogenesis is essential for tumor ...
Thalomid (thalidomide) dosing, indications, interactions, adverse effects, and more
VEGFInhibitionTumorsAnti-angiogenesisMTORBevacizumabTumor growth and metastasisInhibitsMetastasisStimulatorsPARP InhibitorsTipped in favorEndothelialInflammatoryInhibit angiogenesisReceptorTyrosine kinase inVascularKinase InhibitorAromatase inhibitorApoptosisTherapeuticPotent inhibitorsTherapies calledMediatorsProliferationEndogenousEnzymeCardiacAntibodyGrowthOccursTissueImatinibVivoAntiangiogenicClinicalProteinKinasesAbnormalMedicationsBlood
VEGF23
- In recent years, the vascular endothelial growth factor (VEGF) has become one of the main objectives in treating tumour-induced angiogenesis. (revistanefrologia.com)
- Various studies have shown that the anti-VEGF monoclonal antibody, bevacizumab, can reduce angiogenesis and inhibit solid tumour growth. (revistanefrologia.com)
- The postponed curing of gastric ulcers continues to be attributed to the power from the Helicobacter pylori to create angiogenic inhibitors, whereas, decreased VEGF amounts are in charge of repeated CP-724714 aphthous ulcerations. (bibf1120.com)
- The VEGF 165 dependent Matrigel plug assay was performed to verify the antiangiogenic potential of LHT7 on a VEGF 165 inhibitor. (elsevier.com)
- Systemic hypertension is a potential complication of certain cancer therapies, including vascular endothelial growth factor (VEGF) signaling pathway inhibitors, alkylating agents, taxanes, proteasome inhibitors, pyrimidine analogs, and vinca alkaloids. (acc.org)
- The VEGF signaling pathway is critical to angiogenesis and can be inhibited by monoclonal antibodies and small molecule tyrosine kinase inhibitors directed at VEGF and its receptor, respectively. (acc.org)
- 9 Whereas some retrospective analyses have postulated that VEGF signaling pathway inhibitor-induced hypertension might correlate with anti-tumor response, this has yet to be validated in large prospective studies. (acc.org)
- Vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are the main factors promoting angiogenesis [ 7 , 8 ]. (hindawi.com)
- Anti-VEGF therapy is effective in inhibiting angiogenesis and metastasis of tumor [ 9 , 10 ]. (hindawi.com)
- Chemically modified heparin shows a significantly reduced anticoagulant activity and enhanced ability to interact with FGF, VEGF, and hepatocyte growth factor, which are known to stimulate angiogenesis [ 13 ]. (hindawi.com)
- . Although VEGF inhibitors reduce angiogenesis and vascular permeability, there is no disease resolution or complete vessel regression. (medindia.net)
- Nous avons déterminé la concentration d'endostatine et de VEGF dans le sérum de 20 femmes non enceintes en bonne santé et de 64 femmes enceintes : 20 en bonne santé, 20 ayant une prééclampsie bénigne et 24 une prééclampsie grave. (who.int)
- Oxygen tension and cytokines have been shown to influence trophoblast VEGF expression, suggesting that this particular family of angiogenic proteins plays an important role in placental angiogenesis [3]. (who.int)
- We investigated the relationship of VEGF as an angiogenic growth factor and endostatin as an angiogenic inhibitor in patients with pre-eclampsia. (who.int)
- Earlier studies characterized bevacizumab as species specific and lacking the ability to neutralize murine (m) VEGF-A. However, a recent study reported that bevacizumab is a potent inhibitor of hemangiogenesis and lymphangiogenesis in murine models. (arvojournals.org)
- 3 4 One of the key mediators of physiological and pathologic angiogenesis is vascular endothelial growth factor (VEGF)-A. 5 Early studies show that VEGF-A is increased in the eye fluids of patients with ischemic retinal disorders 6 or in neovascular membranes of patients with age-related macular degeneration (AMD). (arvojournals.org)
- 7 Two VEGF inhibitors, pegaptanib 8 and ranibizumab, 9 have been approved by the United States Food and Drug Administration (FDA) for the therapy of neovascular AMD. (arvojournals.org)
- Indeed, much research supports the notion that VEGF-A plays an important role in corneal angiogenesis. (arvojournals.org)
- Similarly, expression of AKT dominant negative mutant also inhibited angiogenesis and tumor growth, and decreased the expression of HIF-1 alpha and VEGF in the tumor xenographs. (cdc.gov)
- In addition, we found that AKT is the downstream target of PI3K in controlling angiogenesis and tumor growth, and PTEN could inhibit angiogenesis by regulating the expression of HIF-1 and VEGF expression through AKT activation in PC-3 cells. (cdc.gov)
- It inhibited SCF- and VEGF-induced angiogenesis of human umbilical vein endothelial cells that express the SCF receptor KIT, with IC50 values of 5.2 nM and 5.1 nM, respectively. (lclabs.com)
- In fact, diabetes reduces the rate of angiogenesis by alteration in the expression angiogenic genes such as vascular endothelial growth factor (VEGF) [6] . (eg.net)
- PURPOSE: Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, which is crucial in cancer progression. (greenmedinfo.com)
Inhibition7
- Topical VS application suppresses the progression of laser-induced CNV via angiogenesis inhibition and may constitute a therapeutic alternative for excessive neovascularization occurring with ocular diseases. (molvis.org)
- Inhibition of angiogenesis can control tumor metastasis and improve the prognosis [ 3 - 6 ]. (hindawi.com)
- In this study, by using chicken chorioallantoic membrane (CAM) and in nude mice models, we demonstrated that inhibition of PI3K activity by LY294002 decreased PC-3 cells-induced angiogenesis. (cdc.gov)
- These results suggest that inhibition of PI3K signaling pathway by PTEN inhibits tumor angiogenesis and tumor growth. (cdc.gov)
- E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. (lclabs.com)
- Biochemical Profiling of Clinical Kinase Inhibitors To relate the anti-proliferative activity of kinase inhibitor medications towards the inhibition of particular kinase goals, all compounds had been profiled at an individual focus on a -panel greater than 300 biochemical kinase assays (Body 3A, Desk S6) [11]. (conferencedequebec.org)
- The current status of endocrine therapy in the adjuvant and prevention settings was reviewed, and angiogenesis inhibition and apoptosis induction were considered as future promising areas of research. (biomedcentral.com)
Tumors5
- Role of angiogenesis in the growth and progression of tumors. (bvsalud.org)
- To grow beyond a certain size, tumors need to form new blood vessels in a process called angiogenesis . (cancer.gov)
- Aside from its anticoagulant action, heparin binds to various growth factors, cytokines, and extracellular proteins and consequently is able to affect migration of cancer cells and angiogenesis in tumors. (hindawi.com)
- Angiogenesis is the formation of new blood vessels, a process that aids the development of cancerous tumors. (asbestosnetwork.com)
- RESULTS: We show that flaxseed, enterodiol, and enterolactone counteracted E2-induced growth and angiogenesis in solid tumors. (greenmedinfo.com)
Anti-angiogenesis3
- Thus, effective anti-angiogenesis therapies that could be continuously administrated through a noninvasive route are in demand for long-term control of CNV. (molvis.org)
- Understanding the role of eicosanoids in tumorigenesis is of direct clinical relevance as the pharmacologically accessible autacoids system, such as EETs, may offer an entirely new system of targets for anti-stromal and anti-angiogenesis strategies in cancer therapy. (harvard.edu)
- In addition, we initiated patient enrollment at multiple sites around the world in TIVO-1, which is the first ever Phase 3 study in RCC designed to evaluate superiority in a head-to-head comparison against a widely prescribed anti-angiogenesis therapy in first-line RCC. (flagshippioneering.com)
MTOR3
- Identification of aberrant tumor angiogenesis and hyperactive mammalian target of rapamycin (mTOR) pathways as drivers of NET progression has provided a framework for the development and clinical testing of new drugs. (cancernetwork.com)
- However, additional kinase medicines inhibit the development of multiple cell lines, such axitinib, ponatinib, bosutinib, sunitinib and crizotinib, which cluster collectively in heat map (Number 2C), the mTOR inhibitors temsirolimus and everolimus, as well as the MEK inhibitor trametinib (Number 2C). (conferencedequebec.org)
- mTOR, a serine/threonine kinase, is thought to play a central role in regulating cell growth, proliferation, cellular metabolism and angiogenesis [ 7 ]. (jcancer.org)
Bevacizumab2
- Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels, to treat various cancers. (eurekalert.org)
- 12 reported that bevacizumab potently inhibits corneal angiogenesis and lymphangiogenesis. (arvojournals.org)
Tumor growth and metastasis3
- Although heparin can regulate angiogenesis, tumor growth and metastasis, its clinical application, as well as that of low-molecular heparin (LMWH), for treating cancer are limited because of heparin's anticoagulant activity and risk of hemorrhages. (elsevier.com)
- Recent studies have showed that angiogenesis plays a crucial role in tumor growth and metastasis. (hindawi.com)
- In both cases increased EETs dramatically stimulated angiogenesis, tumor growth, and metastasis. (harvard.edu)
Inhibits1
- Thymidine phosphorylase inhibitor inhibits degradation of FTD and inhibits angiogenesis. (selleckchem.com)
Metastasis6
- Angiogenesis has an important role in metastasis development. (revistanefrologia.com)
- The development of new blood vessels (angiogenesis) is necessary to sustain the growth of primary tumor as well as a process of tumor metastasis . (bvsalud.org)
- The present study was performed to investigate the effect of N-desulfated heparin on basic fibroblast growth factor (bFGF) expression, tumor angiogenesis and metastasis of gastric carcinoma. (hindawi.com)
- N-desulfated heparin can inhibit the metastasis of gastric cancer through inhibiting tumor bFGF expression and tumor angiogenesis with no obvious anticoagulant activity. (hindawi.com)
- In this study, we investigated the effect of N-desulfated heparin on bFGF expression, angiogenesis, and tumor metastasis in vitro and in vivo. (hindawi.com)
- c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. (newdrugapprovals.org)
Stimulators4
- Angiogenesis, which is the process by which new blood vessels develop from preexisting vessels, is governed by a very complex network of opposing signals that, under normal physiological conditions, are elicited by various highly regulated angiogenesis stimulators and inhibitors [ 1 ]. (hindawi.com)
- During tumor-associated angiogenesis, the balance of angiogenesis stimulators and inhibitors is tipped in favor of angiogenesis by hypoxia-inducible factor-1 gene expression [ 2 ]. (hindawi.com)
- When inhibitors are present in excess of stimulators, angiogenesis is stopped. (angio.org)
- In general, angiogenesis is "turned off" by the production of more inhibitors than stimulators. (angio.org)
PARP Inhibitors1
- Based on Therapeutics Class, the market was studied across Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors. (reportlinker.com)
Tipped in favor1
- When angiogenic growth factors are produced in excess of angiogenesis inhibitors, the balance is tipped in favor of blood vessel growth. (angio.org)
Endothelial4
- Patients underwent serial assessment (pharmacokinetic sampling, biopsy of breast, tumor blood flow dynamic contrast-enhanced magnetic resonance imaging, plasma angiogenesis, and endothelial cell damage markers) prior to treatment, at the end of cycles no. 2 and no. 5, and after mastectomy. (elsevier.com)
- P-selectin, soluble endothelial protein C receptor, soluble thrombomodulin, plasminogen activator inhibitor 1, ADAMTS-13, von Willebrand factor, tissue factor, soluble intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 were more elevated in LF patients than in controls. (cdc.gov)
- Endothelial protein C receptor, thrombomodulin, intercellular adhesion molecule 1, plasminogen activator inhibitor 1, D-dimer, and hepatocyte growth factor were higher in fatal than nonfatal LF cases. (cdc.gov)
- Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. (greenmedinfo.com)
Inflammatory5
- Key compounds of the cytochrome-P450, a major enzyme pathway may influence angiogenesis and control movement of inflammatory cells to the affected area. (medindia.net)
- The findings of the study seem to suggest that targeting the cytochrome-P450 pathway could have important therapeutic implications in the treatment of AMD and other inflammatory conditions characterized by angiogenesis (including cancer) by increasing the expression of these lipid mediators. (medindia.net)
- Inflammatory processes in the tumor stroma are increasingly implicated in tumorigenesis and associated angiogenesis. (harvard.edu)
- Steroids are also potent inhibitors of the inflammatory enzyme cascade, angiogenesis, and mast-cell degranulation. (medscape.com)
- Our work defined how the COX-2 pathway regulated angiogenesis, cancer and inflammatory disease. (harvard.edu)
Inhibit angiogenesis1
- Drugs that inhibit angiogenesis could offer a treatment that is complementary to traditional chemotherapy . (bvsalud.org)
Receptor5
- Once the potent NK and GBM cell receptor-ligand interactions are determined, NK cells will be combined with humanised antibodies against tumour antigens such as NG2/CSPG4,EGFR, or combined with proteasome inhibitors to potentiate tumour killing. (uib.no)
- Lenvatinib, also known as E7080, is an active inhibitor of multiple receptor tyrosine kinases, with IC50 values of 22 nM (VEGFR1), 4 nM (VEGFR2), 5.2 nM (VEGFR3), 46 nM (FGFR1), 51 nM (PDGFRa), 39 nM (PDGFRb), and 100 nM (KIT). (lclabs.com)
- The pivotal study evaluated the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. (merck.com)
- In addition, our work contributed to the development of S1P receptor inhibitors, which are being tested and used for treatment of a number of autoimmune diseases. (harvard.edu)
- LY2801653 , also known as Merestinib, is a n orally available, small molecule inhibitor of the proto-oncogene c-Met (mesenchymal-epithelial transition, also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. (newdrugapprovals.org)
Tyrosine kinase in2
- KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients. (merck.com)
- Method: Here, we investigated the immunologic phenotypes (CD38/CD69/HLA-DR/CD28/CD57/BTLA/TIGIT/PD-1) of T subsets (TN, TCM, TEM, and TEMRA) in peripheral blood (PB) and bone marrow (BM) from de novo CML patients (DN-CML), patients who achieved a molecular response (MR) and those who failed to achieve an MR (TKI-F) after tyrosine kinase inhibitor (TKI) treatment using multicolor flow cytometry. (bvsalud.org)
Vascular1
- INTRODUCCIÓN: Es un anticuerpo monoclonal, se une con factor de crecimiento vascular endotelial y le impide a los receptores en las células endoteliales. (bvsalud.org)
Kinase Inhibitor2
- Our study displays the energy of merging biochemical and mobile profiling data in the evaluation of kinase inhibitor medication action. (conferencedequebec.org)
- There are (Nov. 2013) twenty-five kinase inhibitor medicines authorized for medical make use of, all except two for malignancy (Desk 1 and Physique 1). (conferencedequebec.org)
Aromatase inhibitor2
- Prolia was later approved to treat men with osteoporosis, glucocorticoid induced osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer and in women receiving aromatase inhibitor therapy for breast cancer. (medlineplus.gov)
- A new concept of evolution of resistance to selective ER modulators was considered, and it was noted that oestradiol can kill both selective ER modulator stimulated and aromatase inhibitor (AI) resistant cells. (biomedcentral.com)
Apoptosis1
- PI3K pathway exerts its function through its downstream molecule AKT in regulating various cell functions including cell proliferation, cell transformation, cell apoptosis, tumor growth and angiogenesis. (cdc.gov)
Therapeutic2
- The current team embarked on this study to determine the possible role of immune cells in angiogenesis and to look for newer and possibly safer and more cost-effective therapeutic options in managing AMD. (medindia.net)
- New treatment principles are emerging in current practice, such as metabolic modulation, therapeutic angiogenesis, and novel interventional techniques (coronary in-flow redistribution and approaches to chronic total occlusion). (nature.com)
Potent inhibitors1
- The marine-sponge derived Hymenialdisines were discovered as potent inhibitors of PK involved in inflammation, thus blocking interleukin-2/TNF-alpha cytokine production. (mdpi.com)
Therapies called2
- Some targeted therapies called angiogenesis inhibitors interfere with these signals to prevent a blood supply from forming. (cancer.gov)
- These mutations respond to targeted therapies called tyrosine kinase inhibitors (TKIs). (healthline.com)
Mediators1
- Specific bioactive mediators of the cytochrome-P450 pathway could influence angiogenesis and prevent associated blindness in age-related macular degeneration according to a recent study conducted by Massachusetts Eye and Ear researchers. (medindia.net)
Proliferation1
- Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. (idrblab.net)
Endogenous1
- This study evaluated the inhibitory effect of vasostatin (VS), an endogenous angiogenesis inhibitor, on CNV. (molvis.org)
Enzyme3
- Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Brain Specific Angiogenesis Inhibitor 1 (BAI1) in serum, plasma, tissue homogenates and other biological fluids. (myelisakit.com)
- Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Brain Specific Angiogenesis Inhibitor 1 (BAI1) in samples from Serum, plasma, tissue homogenates and other biological fluids with no significant corss-reactivity with analogues from other species. (myelisakit.com)
- Fortunately, frankincense extract has proved an effective inhibitor against this enzyme. (our-arthritis.com)
Cardiac3
- Insufficient angiogenesis is certainly characteristic of several disorders, including ischemic tissues damage or cardiac failing, where angiogenesis ought to be enhanced to boost the condition condition. (bibf1120.com)
- Cardiac angiogenesis disruption occurs in diabetes. (eg.net)
- The hydroalcoholic extract of P. crispum did not affect cardiac angiogenesis in normal and diabetic patients, which probably is due to the insufficient amounts of active ingredients, especially flavonoids available in P. crispum . (eg.net)
Antibody1
- Included in revenue for the first quarter is a $5 million development milestone from Biogen Idec related to the AV-203 collaboration, AVEO's ErbB3 inhibitor antibody. (flagshippioneering.com)
Growth7
- Angiogenesis is essential for tumor growth beyond a few millimeters in diameter because of the tumor's requirement for a network of blood vessels to deliver oxygen and nutrients and to remove waste products of metabolism. (hindawi.com)
- Angiogenesis (angio'gen'esis) - the growth of new blood vessels - is an important natural process occurring in the body, both in health and in disease. (angio.org)
- Angiogenesis is the development of new blood vessels in areas of novel tissue growth. (jnccn.org)
- He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein. (audiomedica.com)
- But the direct role and mechanism of PI3K/PTEN signaling in regulating angiogenesis and tumor growth in vivo remain to be elucidated. (cdc.gov)
- Reconstitution of PTEN, the molecular inhibitor of PI3K in PC-3 cells inhibited angiogenesis and tumor growth. (cdc.gov)
- Angiogenesis, the development of new blood vessels from the preexisting ones, is essential for the growth and development of body tissues that can be affected by diabetes [3] , [4] . (eg.net)
Occurs3
- The abnormal angiogenesis occurs in around 10-15 percent of AMD patients, and progresses rapidly ultimately leading to blindness. (medindia.net)
- Angiogenesis occurs in the healthy body for healing wounds and for restoring blood flow to tissues after injury or insult. (angio.org)
- In females, angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and fetus). (angio.org)
Tissue3
- Description: A sandwich quantitative ELISA assay kit for detection of Human Brain Specific Angiogenesis Inhibitor 1 (BAI1) in samples from serum, plasma, tissue homogenates or other biological fluids. (myelisakit.com)
- Anti-heparanase aptamers as inhibitors of angiogenesis and tissue remodelling. (open.ac.uk)
- Further studies are needed to establish the relationship between the initial process of resorption of the blood clot, and the involvement of MMPs 2 and 9 and its regulators/tissue inhibitors. (bvsalud.org)
Imatinib1
- The ABL1 inhibitors imatinib and nilotinib cluster collectively because they selectively inhibit the cell lines A-204 and K-562 that are reliant on ABL1 for development (Number 2C). (conferencedequebec.org)
Vivo1
- In vivo versions Chick chorioallantoic membrane (CAM), rabbit cornea assay, sponge implant versions, matrigel plugs, and standard tumor versions are the traditional angiogenesis versions. (bibf1120.com)
Antiangiogenic1
- Angiogenesis is a simple biological process that's regulated by an excellent stability between pro- and antiangiogenic substances, and it is deranged in a variety of diseases. (bibf1120.com)
Clinical2
- Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use]. (bvsalud.org)
- Open up in another window Physique 1 2D constructions from the kinase inhibitors profiled with this study.Each is kinase inhibitors which were approved for clinical make use of in Nov. 2013. (conferencedequebec.org)
Protein1
- Biologically active marine derived compounds have been shown to represent an interesting source of novel compounds that are protein kinase inhibitors (PKI). (mdpi.com)
Kinases1
- Little molecule inhibitors of proteins kinases certainly are a primary exemplory case of the achievement of targeted therapy. (conferencedequebec.org)
Abnormal1
- The above two compounds were found to protect animal models of the disease from forming abnormal new vessels (angiogenesis). (medindia.net)
Medications3
- These are all oral medications called tyrosine kinase inhibitors (TKIs). (healthline.com)
- Erlotinib is in a class of medications called kinase inhibitors. (medlineplus.gov)
- Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Hepatocellular Carcinoma (HCC)? (medscape.com)
Blood1
- Angiogenesis inhibitors work to prevent this process from happening, in efforts to "starve" the tumor of nutrients and oxygen provided by blood vessels in the body. (asbestosnetwork.com)